Tag Archives: Ottawa

Constance Therapeutics

Tetra Bio-Pharma Reinforces its Development Program by Signing Research & Development Agreement with Constance Therapeutics and Receiving Financial Support from NSERC

Tetra Bio-Pharma Reinforces its Development Program by Signing Research & Development Agreement with Constance Therapeutics and Receiving Financial Support from NSERC

OTTAWA, Ontario, Dec. 13, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that the company has signed an exclusive research and development (R&D) agreement with Constance Therapeutics.

Department of Canada: Proposed Excise Duty Framework for Cannabis Products and Finance Ministers

Finance Ministers Reach Agreements on Behalf of All Canadians

OTTAWA, Ont., Dec. 11, 2017 /Weed Wire/ — Canada works best when governments work collaboratively to take actions that are in the interest of all Canadians, strengthen the middle class and help those working hard to join it. Federal, provincial and territorial Finance Ministers met today in Ottawa to build on their productive partnership, discuss issues that are top of mind for Canadians, and make further progress on important joint priorities.

Constance Therapeutics

Tetra Bio-Pharma Opens Markets at TSX Listing Ceremony

OTTAWA, Ontario, Dec. 6, 2017 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development, is pleased to announce that Tetra opened the Toronto Stock Exchange (“TSX”) yesterday at a ceremony to recognize the listing and trading of Tetra, which began on August 16th 2017 under the symbol TBP.

Drug-impaired driving Excise Duty Framework public education symposium Legislation White paper Mandatory Testing Health Canada Cannabis Use and public consultation

Don’t Drive High: Public Awareness Campaign Launches Today

OTTAWA, Ontario, Dec. 5, 2017 /Weed Wire/ – Today, the Honourable Ralph Goodale, Minister of Public Safety and Emergency Preparedness, launched the Government of Canada’s drug-impaired driving public awareness campaign to communicate to Canadians the risks associated with driving under the influence of cannabis and other drugs.

2Badgers Consulting cci Maurizio Calconi

CCI Appoints Mr. Maurizio Calconi as Vice President for CCI Staffing Solutions, a division of Cannabis Compliance Inc.

OTTAWA, Ontario, Dec. 4, 2017 /Weed Wire/ – Cannabis Compliance Inc., (CCI) of Toronto, Ontario is pleased to announce the appointment of Mr. Maurizio Calconi to the CCI team as VP of CCI’s Staffing Solutions division.

2Badgers Consulting cci Maurizio Calconi

CCI and NAC Announce Manitoba Tender Intentions

OTTAWA, Ontario, Dec. 4, 2017 /Weed Wire/ – Cannabis Compliance Inc. (“CCI”) is pleased to announce that it is working with National Access Cannabis Corp. (“NAC”), providing technical services in connection with NAC’s anticipated proposal to the Manitoba Request for Proposal for Retail Cannabis stores (RFP 10QGET-CRS-2017) (the “RFP”) due December 22, 2017.

Constance Therapeutics

Tetra Bio-Pharma’s Business Model and Commercialization Strategy In Line with the Canadian Government’s Proposed Approach to the Regulation of Cannabis

OTTAWA, Ontario, Nov. 22, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that the Canadian Government’s Proposed Approach to the Regulation of Cannabis further confirms the strategic direction of its business model, and that the company is in an excellent position to commercialize natural health products and drugs post-legalization for both the pet and human markets.

Canadian Pharmacists Association ( CPhA )

Pharmacists Disappointed with Proposed Cannabis Regulations, Concerned with Impact to Medical Cannabis Patients

OTTAWA, Ontario, Nov. 22, 2017 /Weed Wire/ — The Canadian Pharmacists Association (CPhA) is disappointed that the federal government’s proposed regulatory approach to cannabis continues to miss the mark on several key issues, displaying an ongoing lack of concern for medical cannabis patients.

Drug-impaired driving Excise Duty Framework public education symposium Legislation White paper Mandatory Testing Health Canada Cannabis Use and public consultation

Health Canada Launches Public Consultation on Proposed Approach to the Regulation of Cannabis

OTTAWA, Ont., Nov. 21, 2017 /Weed Wire/ — The current approach to cannabis does not work. Earlier this year, the Government of Canada introduced Bill C-45, the proposed Cannabis Act, to legalize, strictly regulate and restrict access to cannabis. Bill C-45 aims to keep cannabis out of the hands of Canadian youth and the profits away from criminals and organized crime.

Sundial Growers Cannabis Canada Association

Statement on the Government of Québec’s plan for the Regulation of Cannabis

OTTAWA, Ontario, Nov. 21, 2017 /Weed Wire/ — Cannabis Canada, and the licensed producers of medical cannabis that it represents, share Province’s commitment to ensuring adult Quebecers have access to safe, regulated cannabis products and support the Government’s decision to make clear its intentions regarding the distribution and retail of adult-use cannabis.

Constance Therapeutics

Tetra Bio-Pharma Inc.: Rx Princeps(TM) Now Available for Patients through Licenced Producer Partner Aphria

OTTAWA, Ontario Nov. 16, 2017 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that Rx Princeps(TM), unique blend of dried medical cannabis used in its PPP001 clinical trials, is now available through licensed producer Aphria Inc. (“Aphria”) under Access to Cannabis for Medical Purposes Regulations (ACMPR).

Sundial Growers Cannabis Canada Association

Statement on the Government of Canada’s Approach to Cannabis Taxation

OTTAWA, Ontario, Nov. 14, 2017 /Weed Wire/ — Cannabis Canada, and the licensed producers of medical cannabis it represents, share the Government of Canada’s commitment to regulating and restricting access to cannabis to keep it out of the hands of youth, and the profits out of the hands of criminals.

Drug-impaired driving Excise Duty Framework public education symposium Legislation White paper Mandatory Testing Health Canada Cannabis Use and public consultation

Government of Canada Announces Consultation on Proposed Excise Duty Framework for Cannabis Products

OTTAWA, Ontario, Nov. 14, 2017 /Weed Wire/ — The Department of Finance Canada today published for consultation a proposed excise duty framework for cannabis products. The proposed level of taxation is intended to keep prices low to eliminate the black market, as discussed at the Finance Ministers Meeting last June.

Drug-impaired driving Excise Duty Framework public education symposium Legislation White paper Mandatory Testing Health Canada Cannabis Use and public consultation

Health Canada hosts Partnership Symposium on Cannabis Public Education and Awareness in Ottawa

OTTAWA, Ontario, Nov. 10, 2017 /Weed Wire/ — Today, Health Canada hosted a one-day public education symposium with approximately 90 representatives from federal, provincial and territorial governments, Indigenous groups, and health and other partner organizations that play a role in raising awareness and educating Canadians about the health and safety risks of cannabis use.

Department of Canada: Proposed Excise Duty Framework for Cannabis Products and Finance Ministers

Government of Canada Announces Consultation on Proposed Excise Duty Framework for Cannabis Products

OTTAWA, Ont., Nov. 10, 2017 /Weed Wire/ — The current approach to cannabis is not working, and the Government of Canada is committed to legalizing, regulating and restricting access to cannabis to keep it out of the hands of kids, and profits out of the hands of criminals.

Constance Therapeutics

Tetra Bio-Pharma Concludes its First Sale of Rx Princeps(TM) Inhalation Device

OTTAWA, Ontario, Nov. 9, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced its first sale of its Rx Princeps(TM) inhalation device. The sale of this inhalation device is the first step towards the sale of Rx Princeps(TM).

Drug-impaired driving Excise Duty Framework public education symposium Legislation White paper Mandatory Testing Health Canada Cannabis Use and public consultation

Government of Canada to Invest in Cannabis Education and Awareness

OTTAWA, Ontario, Oct. 31, 2017 /Weed Wire/ — The Government of Canada introduced legislation to legalize, strictly regulate and restrict access to cannabis to keep it out of the hands of Canadian youth and the profits from criminals and organized crime.

Constance Therapeutics

Tetra Bio-Pharma Goes After the Cannabis Oil Medical Market and Launches a Phase 4 Trial with Cannabis Oils in Partnership with Santé Cannabis

OTTAWA, Ontario, Oct. 26, 2017 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the launch of a medical cannabis oil program as it targets penetrating the lucrative cannabis oil market and strengthens its plans to generate revenues from the medical cannabis market.

Constance Therapeutics

Tetra Bio-Pharma Hires Medical Science Liaison to Promote Rx Princeps(TM) and Presents its New Corporate Image

OTTAWA, Oct. 19, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the hiring of Dr. Vincent Jourdain, Ph. D. as medical science liaison (MSL).

Constance Therapeutics

Tetra Bio-Pharma Signs Agreement with Partner Aphria to Start Promoting Rx Princeps(TM), its Medical Cannabis Blend, under ACMPR

OTTAWA, Ontario, Oct. 18, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that it will start promoting a co-developed medical cannabis blend product under Access to Cannabis for Medical Purposes Regulations (ACMPR).

Constance Therapeutics

Tetra Bio-Pharma Continues Forward into the Veterinary Ophthalmology Market by Entering into an Agreement with Drs. Cullen and Webb

OTTAWA, Ontario, Oct. 12, 2017 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the addition of two members to its clinical advisory board for the veterinary market – Dr. Cheryl Cullen, an American Board-certified Veterinary Ophthalmologist, and Dr. Webb, an American Board of Veterinary Ophthalmology (ABVO) Resident.

Constance Therapeutics

Tetra Bio-Pharma Selected to Present at Prestigious BIO Investor Forum In San Francisco October 17-18

OTTAWA, Ontario, Oct. 4, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug discovery, today announced that it has been selected, among a large group of candidates, to present at the prestigious BIO Investor Forum to be held in San Francisco October 17-18th at the Westin St. Francis Hotel.

Constance Therapeutics

Tetra Engages in Innovative Air Analysis and Development of Specific Air Cleaning Devices with AES Environment for the Commercialization of PPP001 and for Marijuana Consumer Market

OTTAWA, Ontario, Sept. 28, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that it has signed a letter of intent (LOI) with AES Environment Group to develop and commercialize specific products ensuring the safety of caregivers for patients who will use PPP001 or medical cannabis.

Constance Therapeutics

Tetra Bio-Pharma to Engage in Co-Development and Distribution Partnership With Major Healthcare Specialty Distributor

OTTAWA, Ontario, Sept. 20, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that it has signed a letter of intent (LOI) with a major player of the healthcare specialty industry.

Cannabis Compliance Inc.

Cannabis Compliance Forms A Strategic Partnership For Secure Transport Of Cannabis

TORONTO, Sept. 19, 2017 /Weed Wire/ – Cannabis Compliance Inc., (CCI) of Toronto, Ontario, Canada, is pleased to announce the formation of a strategic partnership with 3|Sixty Secure Corp. of Ottawa, Ontario, Canada, to provide the ultimate in security, transport and compliance for Canadian medical marijuana.

Canadian Cannabis Legalization Hearings Happening in Parliament Right Now

Canadian Cannabis Legalization Hearings Happening in Parliament Right Now

On Sept. 11, 2017, Canada’s House of Commons health committee returned to Parliament Hill in Ottawa to begin the first of five full-day hearings on Canadian cannabis legalization.

Cannabis Canada

Cannabis Canada Statement on the Government of Ontario’s Announcement on the Province’s Approach to the Federal Legalization of Cannabis

OTTAWA, Ont., Sept. 8, 2017 /Weed Wire/ — Cannabis Canada, and the licenced producers of medical cannabis that it represents, share the Province’s commitment to ensuring adult Ontarians have access to safe, regulated cannabis products and support the Government’s decision to make clear its intentions regarding the distribution and retail of recreational cannabis.

Constance Therapeutics

Tetra Bio-Pharma to Attend the 10th Annual International Partnering Conference – BioPharm America

OTTAWA, Ontario, Sept. 8, 2017 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug discovery, today announced that its Vice President of Business Development, Mr. Bob Bechard, is scheduled to attend the 10th Annual International Partnering Conference, BioPharm America, September 26-27 at the Sheraton Boston Hotel.

Constance Therapeutics

Tetra Bio-Pharma to Benefit from Intellectual Properties Created within the Cannabis Health Research Chair from the University of New Brunswick

OTTAWA, Ontario, Aug. 31, 2017 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP) (OTCQB:TBPMF), today announced that it will benefit from the intellectual property (IP) created within the cannabis health research Chair (The Chair) from the University of New Brunswick (UNB).

Appointments Constance Therapeutics Bernard Fortier

Tetra Bio-Pharma Strengthens its Management Team in Preparation for the Initiation of its Commercial Activities

OTTAWA, Ontario, Aug. 29, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), today announced that it has strengthened its management team in preparation for the initiation of its commercial activities with the appointments of Dr. Anne-Sophie Courtois to the position of Vice President, Marketing effective immediately and Mr. Bernard Lessard to the position of Chief Financial Officer (CFO), effective September 18, 2017.

Constance Therapeutics

Tetra Bio-Pharma’s Clinical Research Partner, Altasciences, offers Innovative Cannabis Research Solutions

OTTAWA, Ontario, Aug. 28, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF) and Altasciences are pleased to share that they are in the final stages of completing the world’s first safety and tolerability study on a cannabis extract being developed as a new chemical entity for approval by the FDA and Health Canada as a drug.

Constance Therapeutics

Tetra Bio-Pharma Announces Approval to List on the TSX Venture Exchange

OTTAWA, Ontario, Aug. 16, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (” Tetra ” or the ” Company “) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that its common shares have been approved for trading on the TSX Venture Exchange and that it has applied for voluntary delisting of its common shares from the Canadian Securities Exchange (CSE).

CannaRoyalty

CannaRoyalty Investee, AltMed, Partners with Established Cultivator; Awarded Florida Medical Marijuana License

OTTAWA, Onatario, Aug. 2, 2017 /Weed Wire/ — CannaRoyalty Corp. (CSE: CRZ) (OTCQX: CNNRF) (“CannaRoyalty” or the “Company”), a fully integrated, active investor and operator in the legal cannabis industry, is pleased to announce that one of its investee companies, AltMed, has agreed to combine its Florida operations with Plants of Ruskin Inc. (“Ruskin”), a multi-generational Florida cultivator, to form AltMed Florida.

Constance Therapeutics

Tetra Bio-Pharma Announces Stock Option Grant to CEO

OTTAWA, Ontario, July 25, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), announces that it has made a grant of stock options under its stock option plan to the newly appointed Chief Executive Officer, Bernard Fortier to acquire a total of 400,000 common shares of the Company.

Appointments Constance Therapeutics Bernard Fortier

Tetra Bio-Pharma Signs Letter of Intent with Constance Therapeutics

OTTAWA, Ontario, July 19, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), announced today it has signed a Letter of Intent (LOI) with Constance Therapeutics, Inc. of San Francisco, California, USA, for the clinical development and commercialization in Canada of its signature standardized, patent-pending, medicinal cannabis extract products.

Tetra Bio-Pharma Its Position

Tetra Bio-Pharma Announces Results of Voting at Annual Shareholders’ Meeting & Provides a Corporate Update

OTTAWA, Ontario, July 11, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), is pleased to announce the results of the vote at its July 10, 2017 annual shareholders’ meeting.

Tetra Bio-Pharma Its Position

Tetra Bio-Pharma Strengthens its Position on Bringing Marijuana to Patients in a Form Acceptable to Health Care Professionals

OTTAWA, Ontario, July 5, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), today announced that it has strengthened its position on bringing marijuana to patients in the form of a prescription drug.

Drug-impaired driving Excise Duty Framework public education symposium Legislation White paper Mandatory Testing Health Canada Cannabis Use and public consultation

Statement from the Minister of Health on the ‘Lower-Risk Cannabis Use Guidelines’

OTTAWA, Ont., June 23, 2017 /Weed Wire/ — I welcome the publication of the “Lower-Risk Cannabis Use Guidelines” today in the American Journal of Public Health. The Canadian Institutes of Health Research supported the development of these Guidelines through funding provided to the Canadian Research Initiative in Substance Misuse.

Green bubble? Cannabis investors on white-knuckle ride as share prices fall

Green Bubble? Cannabis Investors on White-Knuckle Ride as Share Prices Fall

Canadian marijuana stocks have been on a punishing slide for three straight months despite a temporary blip of investor fever in April that sent share prices soaring to record highs as Ottawa tabled legislation to legalize pot.

Drug-impaired driving Excise Duty Framework public education symposium Legislation White paper Mandatory Testing Health Canada Cannabis Use and public consultation

Statement from Health Canada on Improving the Licensing of Production of Cannabis for Medical Purposes

OTTAWA, Ontario, May 26, 2017 /Weed Wire/ — Health Canada is introducing several improvements to its medical cannabis program that aim to streamline the application process for issuing production licenses and enable increased production under the Access to Cannabis for Medical Purposes Regulations (ACMPR).

Drug-impaired driving Excise Duty Framework public education symposium Legislation White paper Mandatory Testing Health Canada Cannabis Use and public consultation

Statement from Health Canada on Mandatory Testing of Medical Cannabis for Unauthorized Pesticides

OTTAWA, Ontario, May 5, 2017 /Weed Wire/ – Today, Health Canada is announcing that it will require all licensed producers to conduct mandatory testing of all cannabis products destined for sale for the presence of unauthorized pesticides.

Aurora Cannabis eyes expansion with legalization on the horizon

Aurora Cannabis Eyes Expansion With Legalization on the Horizon

As Canada heads toward legalization of marijuana, Alberta producer Aurora Cannabis is focused on expansion with ambitions to raise a $160-million “war chest” from investors who are anxious to profit from what is expected to be a multibillion industry.

Canadian Pharmacists Association ( CPhA )

CPhA Disappointed Medical Cannabis Regime Does Not Enhance Patient Safety

OTTAWA, Canada, April 13, 2017 /Weed Wire/ — The focus of government legislation and regulation in the area of cannabis must be to protect and enhance safety. While the Canadian Pharmacists Association (CPhA) is pleased that today’s federal legislation maintains a separate stream for medical cannabis, we are concerned and disappointed that the legislation fails to enhance patient safety by providing appropriate clinical oversight in the management and dispensing of medical cannabis in Canada.

Cannabis Canada

Cannabis Canada Association Welcomes Government of Canada’s Proposed Cannabis Act

OTTAWA, Ontario, April 13, 2017 /Weed Wire/ — Cannabis Canada, the leading organization of companies that hold Health Canada licenses to cultivate and sell medical cannabis, welcomes the legislation tabled today by the Government of Canada to legalize, regulate, and restrict access to cannabis.

Marijuana industry faces challenge in gaining Canadians’ trust, survey finds

Marijuana Industry Faces Challenge in Gaining Canadians’ Trust

Marijuana stocks may have leapt higher on the news of Ottawa’s plans to legalize the drug by next year, but the industry is facing an uphill battle in building trust with Canadian consumers, according to a new survey.

Trudeau to Legalize Marijuana by July 2018, CBC Reports

Trudeau to Legalize Marijuana by July 2018, CBC Reports

Canadian Prime Minister Justin Trudeau’s government will introduce legislation to legalize marijuana by July 1, 2018, according to a report from CBC News, a move that follows through on one of his Liberal Party’s campaign pledges.


Page 1 of 212
Top